brain atrophy

May 22, 2019May 22, 2019

Simvastatin, Common Statin, Treats SPMS in Ways Distinct from Cholesterol, Study Suggests

News

Simvastatin, a widely prescribed statin that works to lower cholesterol levels, may slow brain atrophy and disease progression in people with secondary progressive multiple sclerosis (SPMS) for reasons unrelated to ... Read more

April 4, 2019May 6, 2019

#AANAM – Ibudilast Slows Brain Atrophy in PPMS But Not SPMS Patients, Phase 2b Trial Shows

News

Treatment with oral ibudilast slows brain shrinkage in patients with primary progressive multiple sclerosis (PPMS), but not in those with secondary progressive MS (SPMS), according to results of a Phase ... Read more

March 18, 2019March 20, 2019

Temelimab Provides Long-term Benefits in RRMS Patients, Extension Study Shows

News

Two-year treatment with temelimab reduced brain atrophy, or shrinkage, preserved myelin, and reduced disease progression in patients with relapsing-remitting multiple sclerosis (RRMS), according to findings from an extension study of ... Read more

February 22, 2019March 20, 2019

Aubagio, Tecfidera Show Comparable Effectiveness in Relapsing MS, Real-world Phase 4 Trial Finds

Aubagio, News

Aubagio (teriflunomide) seems to be superior to Tecfidera (dimethyl fumarate) in slowing whole brain shrinkage in patients with relapsing multiple sclerosis (MS), a new Phase 4 clinical trial shows. However, Aubagio and Tecfidera ... Read more

January 28, 2019February 1, 2019

MS News that Caught My Eye Last Week: Herbicide and MS, ‘Incredible’ Foot Stimulators, Tysabri and Brain Shrinkage

Columns, The MS Wire - A Column by Ed Tobias

Herbicide Called Linuron Seen to Trigger Inflammatory Signals Linked to MS in Study This is only a mouse study, but this herbicide has been banned in Europe because of ... Read more

October 18, 2018October 18, 2018

#ECTRIMS2018 – GNbAC1 Shows Consistent Neuroprotection in RRMS Patients, Phase 2b Study Reports

News

Treating relapsing-remitting multiple sclerosis (RRMS) patients with GeNeuro’s investigational compound GNbAC1 lessened brain atrophy and lesion load and suggested myelin preservation, according to results of a Phase 2b study. Importantly, ... Read more

October 18, 2018October 25, 2018

#ECTRIMS2018 – Role of Brain Atrophy in MS Progression Poorly Understood by Patients, MSAA Survey Finds

News

Although brain atrophy — the loss of brain volume — is an increasingly important measure in multiple sclerosis trials and treatment outcomes, MS patients have a limited understanding of ... Read more

October 17, 2018October 17, 2018

#ECTRIMS2018 – Blood Level of Neurofilament Light Chain May Predict Brain Atrophy in Progressive MS, Study Suggests

News

Measuring the blood level of neurofilament light chain (NfL) may predict brain shrinkage in primary progressive (PPMS) and secondary progressive multiple sclerosis (SPMS), according to a new study. The ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018: Study Proposes Serum Neurofilament Light Threshold to Identify RRMS Patients at Risk of Worsening

News

Relapsing-remitting multiple sclerosis (RRMS) patients with serum neurofilament light chain (sNfL) levels higher than a proposed threshold have a higher risk of disease activity, and worsened disability, lesions and ... Read more

September 19, 2018September 19, 2018

GeNeuro to Develop the MS Clinical Program of GNbAC1 Without Servier

News

GeNeuro announced it has reacquired from Servier the worldwide rights to commercialize and develop the investigational humanized antibody GNbAC1 for the treatment of multiple sclerosis (MS). The decision came after Servier, a ... Read more

September 18, 2018September 20, 2018

Ibudilast Slows Brain Shrinkage 48% in Progressive MS Patients in Phase 2 Trial; Lead Researcher Says Finding is ‘Remarkable’

News

Progressive multiple sclerosis patients — with primary or secondary progressive disease — treated with high doses of oral ibudilast in a Phase 2 clinical trial showed a 48 percent slowing in ... Read more

August 20, 2018August 20, 2018

Hypertension and Heart Disease Linked to Increase in Brain Atrophy in Long-term Study

News

High blood pressure and heart disease are linked to greater loss of brain mass, or atrophy in white matter and whole brain volume, in people with multiple sclerosis (MS), ... Read more

July 17, 2018July 17, 2018

Managing High Blood Pressure Important for Managing MS, Study Suggests

News

An association between high blood pressure and reduction of brain integrity in multiple sclerosis (MS) patients highlights the importance of blood pressure management by MS healthcare providers. The severity ... Read more

April 26, 2018April 30, 2018

#AAN2018 – MS Progresses Quickly in African-Americans and May Warrant Aggressive Treatment

News

Multiple sclerosis in African-Americans progresses much faster than in Caucasian patients, new research reports, suggesting that blacks would benefit from a more aggressive treatment approach. Led by researchers at ... Read more

April 20, 2018May 21, 2018

#AAN2018 – Switching from Rebif to Ocrevus Improves MS, Extension Study Shows

News, Ocrevus

Continuous treatment with Ocrevus (ocrelizumab) or switching from Rebif (interferon beta-1a) to Ocrevus leads to a significant long-term reduction in relapsing multiple sclerosis activity, a two-year extension study shows. Ocrevus’s maker, ... Read more

April 19, 2018April 19, 2018

#AAN2018 — Investigational Therapy Ibudilast Slows Brain Atrophy in Phase 2 Trial for Progressive MS

News

Investigational therapy ibudilast leads to a significant reduction of brain atrophy, supporting its potential to effectively treat progressive multiple sclerosis (MS), new data from a Phase 2 clinical trial show. These ... Read more

March 29, 2018March 30, 2018

GeNeuro-Servier Antibody Limits RRMS Patients’ Brain Shrinkage, Phase 2b Trial Shows

News

The laboratory-generated antibody GNbAC1 continued to limit brain shrinkage a year after relapsing-remitting multiple sclerosis patients began receiving it, its developers announced. GeNeuro and Servier were reporting on the 12-month results of a Phase ... Read more

February 2, 2018February 2, 2018

#ACTRIMS2018 – MediciNova Presents Positive Results from SPRINT-MS Trial Evaluating Ibudilast in Progressive MS

News

Top-line results from a clinical trial evaluating the investigational oral therapy ibudilast for progressive multiple sclerosis (MS) show that the therapy led to a significant reduction of brain atrophy ... Read more

January 19, 2018January 19, 2018

Loss of Deep Grey Matter in Brain Linked to Greater Disability, MS Progression in Study

News

Deep grey matter volume loss in the brain drives multiple sclerosis (MS) progression and disability, and is particularly evident in people with progressive forms of the disease, a retrospective ... Read more

October 30, 2017October 31, 2017

#MSParis2017 – Ibudilast Slows Loss of Brain Tissue in MS Patients, Phase 2 Trial Shows

News

The Japanese company MediciNova‘s anti-inflammatory agent ibudilast slows multiple sclerosis patients’ brain shrinkage and their loss of the protective myelin coating around nerve cells, a Phase 2 clinical trial shows. Robert ... Read more

July 6, 2017July 6, 2017

Lipoic Acid, an Over-the-counter Antioxidant, Seen to Slow Brain Atrophy in SPMS Patients

News

The over-the-counter antioxidant lipoic acid slowed brain deterioration in patients with secondary progressive multiple sclerosis (SPMS), according to a pilot study. An Oregon Health & Science University research team conducted ... Read more

December 15, 2016December 15, 2016

Brain Atrophy in Secondary Progressive MS Linked in Study to High Levels of Free Hemoglobin in Blood

News

Hemoglobin leaking from injured red blood cells may be associated with brain atrophy in secondary progressive multiple sclerosis (SPMS), according to researchers at the Imperial College London, U.K. The study, ... Read more

July 8, 2016July 8, 2016

Brain Atrophy in MS Patients May Soon Be More Easily and Routinely Examined

News

Detecting brain atrophy in multiple sclerosis (MS) patients requires high quality scans, too expensive and complicated for routine clinical use. But this may change with a new software that simplifies ... Read more

March 21, 2016March 21, 2016

CONy16: Should RRMS Disease-Modifying Drugs Be Used to Treat Secondary Progressive MS?

News

A major dilemma facing clinicians is whether to continue treatment with disease-modifying drugs, effective in relapsing-remitting multiple sclerosis (RRMS), as the disease progresses to secondary progressive MS (SPMS). In SPMS,  these ... Read more